Dogwood Therapeutics highlights Halneuron progress, plans SP16 clinical trials

Sep 2, 2026 00:34 (20d ago)

Verifying

Dogwood Therapeutics highlighted progress on Halneuron for chemotherapy-induced neuropathic pain.
Halneuron is a NaV1.7 inhibitor, while SP16 is an LRP1 agonist.
Dogwood Therapeutics announced plans to start clinical trials for SP16.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.